| Objective:To investigate the effects of pioglitazone on bone mineral density and some of bone metabolism biochemicalmarkers (osteoprotegrin,Osteocalcin and Calcitonin) in patients with type 2 diabetes mellitus.Methods:Thirty normal controls,fifty-seven patients were randomly divided into T2DM control group(24 cases) and T2DM experimental group(33 cases).On the basement therapy of blood sugar control,the experimental group served plus pioglitazone(30mg/day) for three months.Dual energy X-ray absorptiometry(DEXA) was used to determin determine the bone mineral density(BMD);enzyme-linked immunosor--bent assay(ELSA) was used to determine OPG level and RIA was used to determine BGP and CT levels.OPG,BGP,CT and BMD were measured and compared after treatment.Results :①OPG level of T2DM was higher than the normal control group(P<0.05) ,BGP and CT levels of T2DM were decreased than the normal control group (P<0.01);②OPG level of T2DM experimental group after pioglitazone treatment was increased.But there was no significant difference between pre-treatment and after treatment(P>0.05);BGP and CT levels of T2DM experimental group after pioglitazone treatment were decreased.There were significant difference between pre-treatment and after treatment(P<0.01);③Hip and lumbar spine BMD of T2DM was decrease than the normal control group(P<0.05);④Hip and lumbar spine BMD of T2DM experimental group were decreased after pioglitazone treatment;⑤OPG level was positively correlated with the diabetes course and postprandial 2 hours blood glucose. Osteocalcin level was positively correlated with age and fasting blood glucose,BGP level was correlated with hip and lumbar spine BMD;CT level was positively correlated with age.Conclusions: Pioglitazone can lead to increase OPG level and decrease BGP and CT level, but decline bone mineral density. This study suggests pioglitazone has adverse effects on bone metabolism.
|
PDF Full Text Request